SecBot SecBot
PRESS-RELEASE ·Filed Sep 9, 2026

IRON

Disc Medicine Inc
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong phlebotomy reduction and hematocrit control data for DISC-3405 in PV significantly de-risks the program. Traders should watch for the upcoming FDA end-of-Phase 2 meeting for selcodebart and initial sickle cell disease data for DISC-3405, both expected by end of 2026, as key catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$74.14
T+0 close · Sep 9, 2026 · via day close
Latest settled
−18.03%
T+20 · $60.77 · next T+60 in 17d
Vs SPY
−20.16%
α at T+20
Latest observation
+12.88%
T+46 · FF3 residual α
  1. T+0 · Sep 10 $74.14entry
  2. T+1 · 2mo ago −5.50%α −6.36% · $70.06
  3. T+5 · 2mo ago −6.69%α −6.19% · $69.18
  4. T+20 · 6w ago −18.03%α −20.16% · $60.77
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing significant phlebotomy reduction and hematocrit control. The company also provided an encore of positive Phase 2 RALLY-MF data for selcodebart in anemia of myelofibrosis. Both programs are advancing toward potential pivotal development, with an FDA end-of-Phase 2 meeting for selcodebart expected by year-end.

Key Facts

  • DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 per 26 weeks (p<0.0001) in PV patients.
  • 61.5% of patients remained phlebotomy-free post-baseline through 26 weeks.
  • Mean hematocrit maintained stably <45% through week 26.
  • DISC-3405 is the first anti-TMPRSS6 mAb to demonstrate phlebotomy reduction in PV patients.
  • Disc plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
  • Selcodebart (DISC-0974) positive Phase 2 RALLY-MF data encore presented; FDA end-of-Phase 2 meeting expected by year-end.
  • PV affects approximately 150,000 patients in the U.S.

Financial Impact

Positive clinical data for two pipeline programs (DISC-3405 in PV, selcodebart in MF) de-risks pivotal development and supports a multi-billion-dollar peak sales opportunity in a large, underserved PV population (~150K U.S. patients). No financial figures provided.

pipeline valueregulatory probability of successpeak sales potential

Risk Factors

  • DISC-3405 is still in Phase 2; larger pivotal trials are needed to confirm efficacy and safety.
  • Competition from existing PV therapies (phlebotomy, cytoreductive agents) and emerging pipeline candidates.
  • Selcodebart's FDA end-of-Phase 2 outcome is uncertain; regulatory path for anemia of MF is not established.
  • Clinical-stage biotech with no approved products; capital needs for pivotal trials may require future financing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3359133

Track record

43 reports on IRON

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026